New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer

Guest Editors:

Dr. Chiara Riganti  
Department of Oncology,  
University of Torino, via Santena 5/bis, 10126 Torino, Italy  
chiara.riganti@unito.it

Dr. Marialessandra Contino  
Department of Pharmacy,  
University of Bari, Bari, Italy  
marialessandra.contino@uniba.it

Deadline for manuscript submissions:  
29 October 2018

Message from the Guest Editors

Dear Colleagues,

“Multidrug resistance” (MDR) cells are often simultaneously resistant to multiple stresses, such as radiotherapy, hypoxia, and nutrient shortages. Of note, MDR cells are also less recognized by the immune system, because they produce immune-suppressive metabolites and poorly raise an anti-tumor adaptive response by the host immune system in response to chemotherapy or radiotherapy. The reasons of this chemo-immune-resistance rely on the superior ability of MDR cells to adapt to stressing conditions. Metabolic rewiring and epigenetic events, such as the expression of specific miRNAs or ncRNAs, play a key role in such adaptation.

This Special Issue will focus on the latest studies dissecting the molecular linkages between chemoresistance and immune-resistance, and on new possible chemo-immune-sensitizer approaches, including radio-chemotherapy or radio-immune-chemo-therapy combinations, metabolic modifiers, and epigenetic modulators.

Dr. Chiara Riganti  
Dr. Marialessandra Contino  
Guest Editors

mdpi.com/si/15016